Inventor · disambiguated record
Yun Mo
Also filed as: MO YUN · MO YUN SUK
8 granted patents·33 pending applications·17 citations·filing 2009–2024
82Inventor score
Files withIRONWOOD PHARMACEUTICALS INC23FOREST LAB HOLDINGS LTD6THERAVANCE BIOPHARMA R&D IP LLC4FOREST LABORATORIES HOLDINGS LTD3FRETZEN ANGELIKA2
Top patents by PatentIndex Score
41 records- 0190US8748573B2Formulations comprising linaclotideFRETZEN ANGELIKA·Filed 2010·Granted Jun 10, 2014·8 cites·10 claims
- 0286US8802628B2Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administrationFRETZEN ANGELIKA·Filed 2009·Granted Aug 12, 2014·7 cites·26 claims
- 0385US2023346881A1Stable Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0485US2024075094A1Low-Dose Stable Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0583US2023310329A1Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0679US2025073301A1Delayed Release Compositions of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0779US2022233635A1Stable Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 0878US10675325B2Stable formulations of linaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2019·Granted Jun 9, 2020·0 cites·18 claims
- 0978US2022125734A1Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1076US2022031802A1Low-Dose Stable Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1175US10702576B2Stable formulations of linaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2019·Granted Jul 7, 2020·0 cites·20 claims
- 1275US10369142B2Combination dosage form of a mu opioid receptor antagonist and an opioid agentTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2017·Granted Aug 6, 2019·1 cites·9 claims
- 1375US9283261B2Linaclotide compositionsFOREST LAB HOLDINGS LTD·Filed 2014·Granted Mar 15, 2016·1 cites·22 claims
- 1475US2021290554A1Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1575US2023398173A1Delayed Release Compositions of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1674US10946009B2Combination dosage form of a mu opioid receptor antagonist and an opioid agentTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Mar 16, 2021·0 cites·14 claims
- 1773US2023142270A1Delayed Release Compositions of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1872US11452723B2Combination dosage form of a mu opioid receptor antagonist and an opioid agentTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Granted Sep 27, 2022·0 cites·11 claims
- 1970US2014287034A1Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2068US2020009216A1Stable Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2166US2020038476A1Low-Dose Stable Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2265US2019029967A1Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2364US2014378393A1Stable Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2464US2016310560A1Low-Dose Stable Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2563US2016310559A1Delayed Release Compositions of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2662US2014018307A1Linaclotide compositionsFOREST LAB HOLDINGS LTD·Filed 2013·Application pending·0 cites
- 2762US2018015139A1Low-Dose Stable Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 2861US2013273169A1Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationFOREST LAB HOLDINGS LTD·Filed 2013·Application pending·0 cites
- 2960US2015132375A1Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 3060US2017157200A1Low-Dose Stable Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 3159US2017281774A1Linaclotide compositionsFOREST LABORATORIES HOLDINGS LTD·Filed 2017·Application pending·0 cites
- 3257US2014005128A1Treatments of gastrointestinal disordersMO YUN·Filed 2011·Application pending·0 cites
- 3356US2016324968A1Linaclotide compositionsFOREST LABORATORIES HOLDINGS LTD·Filed 2016·Application pending·0 cites
- 3456US2025057199A1Method of preparing low-salt pickles using citron vinegarDAMWOO AGRICULTURAL CO LTD·Filed 2023·Application pending·0 cites
- 3555US2020222541A1Linaclotide compositionsFOREST LABORATORIES HOLDINGS LTD·Filed 2019·Application pending·0 cites
- 3654US2015031632A1Orally Disintegrating Compositions of LinaclotideFOREST LAB HOLDINGS LTD·Filed 2014·Application pending·0 cites
- 3752US2016287573A1Combination dosage form of a mu opioid receptor antagonist and an opioid agentTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2016·Application pending·0 cites
- 3846US2014023710A1Milnacipran formulationsFOREST LAB HOLDINGS LTD·Filed 2013·Application pending·0 cites
- 3939US2016015638A1Stable glucokinase activator compositionsVTV THERAPEUTICS LLC·Filed 2015·Application pending·0 cites
- 4039US2010286260A1Milnacipran formulationsFOREST LAB HOLDINGS LTD·Filed 2010·Application pending·0 cites
- 4136US2013012454A1Orally Disintegrating Compositions of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Yun Mo files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →